SCHEMBL3609288

SCHEMBL3609288

CCOC(=O)c1oc2c(Cl)cc(Cl)c(O)c2c1C

nearest known ligand 0.50

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 3/20 0.50
NPC1 O15118 2/20 0.50
MAPT P10636 2/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
ALOX5 P09917 3/20 0.46
SMN1; SMN2 Q16637 1/20 0.45
KMT2A Q03164 4/20 0.44
KDM4E B2RXH2 3/20 0.43
HSD17B10 Q99714 2/20 0.43
CSNK2A2 P19784 1/20 0.40
CSNK2B P67870 1/20 0.40
CSNK2A1 P68400 1/20 0.40
MEN1 O00255 2/20 0.39
HIF1A Q16665 2/20 0.39
GAA P10253 1/20 0.39
ALDH1A1 P00352 1/20 0.38
ALOX15 P16050 1/20 0.38
TSHR P16473 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9739893 0.86 ALOX5 (0.54) RAB9ANPC1MAPTL3MBTL1ALOX5
SCHEMBL3609779 0.84 L3MBTL1 (0.48) RAB9ANPC1MAPTL3MBTL1ALOX5
SCHEMBL3614948 0.79 RAB9A (0.62) RAB9ANPC1MAPTL3MBTL1ALOX5
SCHEMBL9867487 0.78 RAB9A (0.48) RAB9ANPC1MAPTL3MBTL1ALOX5
SCHEMBL10458678 0.74 L3MBTL1 (0.52) RAB9ANPC1MAPTL3MBTL1SMN1; SMN2
SCHEMBL28467690 0.74 RAB9A (0.49) RAB9ANPC1MAPTL3MBTL1SMN1; SMN2
SCHEMBL9867051 0.73 RAB9A (0.41) RAB9ANPC1MAPTL3MBTL1ALOX5
SCHEMBL9739459 0.73 ALOX5 (0.53) RAB9ANPC1MAPTL3MBTL1ALOX5
SCHEMBL10863363 0.73 L3MBTL1 (0.54) RAB9ANPC1MAPTL3MBTL1SMN1; SMN2
SCHEMBL11058465 0.72 RAB9A (0.68) RAB9ANPC1MAPTL3MBTL1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100137298-A1 Biaryl Sulfonamides and Methods for Using Same WYETH (US) 2010-06-03 US disclosed
EP-1692124-B1 BIARYL SULFONAMIDES AS MMP INHIBITORS WYETH CORP (US) 2008-10-15 EP disclosed
US-7420001-B2 Biaryl sulfonamides and methods for using same WYETH (US) 2008-09-02 US disclosed
EP-1692124-A1 BIARYL SULFONAMIDES AS MMP INHIBITORS Wyeth (US) 2006-08-23 EP disclosed
WO-2005061477-A1 BIARYL SULFONAMIDES AS MMP INHIBITORS WYETH (US) 2005-07-07 WO disclosed
US-20050143422-A1 Biaryl sulfonamides and methods for using same WYETH (US) 2005-06-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137298-A1 Biaryl Sulfonamides and Methods for Using Same STS, MMP3, AADAC RAB9A 3864/4885NPC1 2605/4885MAPT 4416/4885
US-20050143422-A1 Biaryl sulfonamides and methods for using same STS, MMP3, AADAC RAB9A 3864/4885NPC1 2605/4885MAPT 4416/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.